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P rostate cancer is one of the most common male cancers [1],  and its incidence has steadily increased,  
especially in recent years [2].  Certain genetic muta-
tions,  either alone or in combination,  have been shown 
to play essential roles in the progression of prostate 
cancer [3-5].  Therefore,  elucidation of the mechanism 
of the gene damage-related response in prostate cells 
would be of great significance in preventing prostate 
cancer progression [6].
The cell cycle checkpoint is the main pathway regu-
lating cell cycle transitions.  Previous studies have sug-
gested that checkpoints can arrest the cell cycle to pro-
vide sufficient time for activating damage-repair genes 
that work to repair the DNA damages generated during 
gene replication [7].  Cell cycle checkpoint loss not only 
results in genomic instability,  but more importantly,  it 
can increase the risk of mutation,  leading to malignant 
tumors [7 , 8].  The subtle genetic changes due to func-
tional polymorphisms in cell cycle-related genes can 
compound the genetic risk of cancer development [9].
RAD17,  which is encoded by Schizosaccharomyces 
pombe,  is one of the cell cycle checkpoint proteins that 
function to mediate DNA damage during replication 
disruption [10].  Recent studies have shown that RAD17 
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Human RAD17,  as an agonist of checkpoint signaling,  plays an essential role in mediating DNA damage.  This 
hospital-based case-control study aimed to explore the association between RAD17 rs1045051,  a missense sin-
gle nucleotide polymorphism (SNP),  and prostate cancer risk.  Subjects were 358 prostate cancer patients and 
314 cancer-free urology patients undergoing treatment at the Zhujiang Hospital of Southern Medical University 
in China.  RAD17 gene polymorphism rs1045051 was evaluated by the SNaPshot method.  Compared with the 
RAD17 gene polymorphism rs1045051 AA genotype,  there was a higher risk of prostate cancer for the CC gen-
otype (adjusted odds ratio [AOR] = 1.731,  95% confidence interval [95%CI] = 1.031−2.908,  p= 0.038).  
Compared with the A allele,  the C allele was significantly associated with the disease status (AOR = 1.302,  
95%CI = 1.037−1.634,  p= 0.023).  All these findings indicate that in the SNP rs1045051,  both the CC genotype 
and C allele may have a substantial influence on the prostate cancer risk.
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is essential for sustained cell growth,  maintenance of 
chromosomal stability and ATR-dependent checkpoint 
activation upon DNA damage [11 , 12].  In addition,  
RAD17 has also been shown to act as a sensor of DNA 
replication progression and may be involved in homol-
ogous recombination [13].
Single nucleotide polymorphisms (SNPs) are DNA 
sequence polymorphisms caused by DNA point muta-
tions that give rise to different alleles,  and are the most 
common type of genetic variation in humans.  SNPs that 
present in the coding region (coding SNPs) result in a 
change of amino acid,  which may be associated with the 
risk of developing particular diseases [14].  SNPs of 
DNA mismatch repair (MMR) system genes have been 
found to be associated with tumorigenesis in various 
cancers [6].  SNPs in the genes of this system may affect 
gene function,  gene expression,  and the effectiveness of 
gene-related systems [10 , 15 , 16].  These findings sug-
gest that the susceptibility of an individual to a particu-
lar cancer may be related to their genotype.  This princi-
ple would also be applicable to RAD17,  as recent studies 
have revealed that in certain Schizosaccharomyces 
pombe RAD17-deleted strains,  the expression of 
RAD17 may result in an inhibition of yeast colony 
growth and retardation of the cell cycle progression [17].
Some studies have revealed an association between 
RAD17 rs1045051 and the risks of esophageal squa-
mous cell carcinoma and colorectal cancer [18 , 19].  
However,  associations between specific SNPs and pros-
tate cancer have not yet been elucidated.  In this study,  
we aimed to investigate the genotype frequencies of the 
RAD17 SNP in a Chinese population and to explore the 
influence of this SNP on the risk of prostate cancer.
Materials and Methods
Ethical approval. All procedures involving 
human participants were in accordance with the ethical 
standards of the institutional and/or national research 
committee and with the 1964 Helsinki Declaration and 
its later amendments or comparable ethical standards.  
The protocol was approved by the Ethics Committee of 
Zhujiang Hospital,  Southern Medical University.
Study subjects. The 672 subjects were patients at 
the Department of Urology,  Zhujiang Hospital,  
Guangzhou in China between January 2015 and April 
2018,  and consisted of 358 patients who were diag-
nosed with histologically confirmed prostate cancer and 
314 cancer-free urology patients.  In this study,  tumor 
stage was determined according to the UICC TNM 
(Unio Internationalis Contra Cancrum Tumor-Node-
Metastasis) classification.  Informed consent was 
obtained from the enrolled subjects after a detailed 
description of the study.  The study was approved by the 
ethics committee of the Zhujiang Hospital of Southern 
Medical University.
In the stratification analysis,  localized and advanced 
prostate cancer were classified according to the follow-
ing criteria: for localized prostate cancer,  T1-2 N0M0,  
Gleason score of 2-7,  and PSA levels ≤ 50 ng/mL; for 
advanced prostate cancer,  T3-4,  N+ or M+,  Gleason 
score of 8-10,  and PSA levels > 50 ng/mL.  Gleason 
grading was performed by experienced pathologists 
based on the 2018 EUA Guidelines.  TNM staging was 
determined by postoperative pathologic presentation or 
according to imaging studies and biopsy reports.
The control group comprised 314 cancer-free men 
who were confirmed to be free of prostate cancer based 
on PSA levels or rectal examination.  Control subjects 
whose total PSA was persistently above 4 ng/mL 
underwent a prostate biopsy to eliminate the possibility 
of prostate cancer.
Blood collection, DNA extraction and genotyping.
A 2-ml aliquot of peripheral blood was collected from 
each subject.  Samples were stored in vacuum tubes 
containing EDTA at −20°C (or −80°C for samples 
stored longer than 1 month).  Genomic DNA was 
extracted using a TIANamp Blood DNA Kit (Tiangen 
Biotech,  Beijing) according to the manufacturer’s 
instructions,  and was quantified to ensure that suffi-
cient DNA could be extracted for the subsequent geno-
typing.  Genotyping and analyses of the RAD17 gene 
polymorphism rs1045051 were performed by the Life 
Technologies Corporation (Shanghai,  China) using an 
ABI SNaPshot® multiplex system.
Multiplex PCR (first PCR). SNaPshot processing 
of genomic DNA was performed at the Zhujiang 
Hospital of Southern Medical University.  Multiplex 
PCR amplification was conducted using a MyCyclerTM 
Thermal Cycler,  with a template based on 1 µL 
genomic DNA (10-50 ng),  2.5 μL 10 × PCR buffer (Mg2+ 
free),  50 mM MgCI2,  2.5 mM of each dNTP,  0.2 µL 
Platinum® Taq (5 U/µL),  and 1 µL first primer mix,  
with ddH2O added to a final reaction volume of 25 µL.  
The program started with a denaturation step of 95°C 
for 5 min followed by 33 cycles of 95°C for 30 sec,  56°C 
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for 30 sec and 72°C for 30 sec,  with a final extension 
step for 5 min at 72°C.  The first PCR primers for 
RAD17 gene polymorphism rs1045051 were as follows:  
upper primer,  5’-ACGTTGGATGGGCAGCAAAAGC 
ACTTTTTC-3’; lower primer,  5’-ACGTTGGATGAT 
CCAGCCTGGACAGTAGAGAC-3’.
The examination of PCR products was performed 
on 2% agarose gel.  Prior to genotyping,  primers and 
dNTPs that were not involved in the reaction were 
removed from the initial PCR process to prevent their 
overreaction in the subsequent extension reactions.  A 
2 µL aliquot of the PCR product was incubated for 
90 min at 37°C in a system that contained 0.3 µL of 
shrimp alkaline phosphatase (SAP,  1 U/µL),  0.2 µL of 
Exo I(20 U/µL) and 7.5 µL of ddH2O,  followed by 
enzyme inactivation for 15 min at 75°C.
SNaPshot reaction. The typing primer provided 
for RAD17 gene polymorphism rs1045051 was 5’-TTT 
TTTTTTTTTTTTTTGGCAATAGCTGAGTTT 
GG-3’.  1 μL of the purified products from the first PCR 
as a template,  1.5 μL of reaction mixture,  and 0.5 μL of 
Probe Mix was prepared for the SNaPshot reactions.  
Reactions were conducted in the MyCyclerTM Thermal 
Cycler under a protocol of 25 cycles at 96°C for 10 sec,  
5°C for 5 sec and 60°C for 30 sec.  A 0.3 µL aliquot of 
SAP (1 U/µL) was then treated for 1 h at 37°C followed 
by heat-inactivation for 15 min at 75°C to remove the 
excess ddNTPs.
Then in an ABI optical plate,  8.8 µL of Hi-DiTM for-
mamide,  0.2 µL of GenescanTM 120 LIZTM Size Standard 
and 1 µL of reaction mixture were combined,  and 
denatured for 5 min at 95°C.  The electrophoresis results 
from the ABI PRISM 3730 DNA Analyzer were ana-
lyzed using GeneMapper software ver. 4.1.
Statistical analysis. The deviation of genotype 
distribution from Hardy-Weinberg equilibrium was 
checked by Chi-square (χ2) test.  The allele and genotype 
data were analyzed based on a reference group of com-
mon allele homozygotes.  Student’s t-test was used for 
continuous variables and chi-square test was used for 
categorical variables to assess differences in the fre-
quency distribution of clinical variables.  The odds ratio 
(OR),  adjusted odd ratio (AOR),  95% confidence 
interval (95%CI) and p values for the association 
between prostate cancer risk and genotypes (or alleles) 
were calculated by logistic regression analysis.
In stratification analyses,  the age at diagnosis (≤ 70 
and > 70 years) and the tumor aggressiveness (both the 
localized and advanced cases) were further estimated as 
stratification factors,  respectively.  The statistical data 
were adjusted for age (at time of diagnosis),  smoking 
and alcohol consumption status during all the processes 
of analyses.  All statistical analyses were performed with 
SPSS 22.0 software (IBM SPSS Statistics; IBM,  Somers,  
NY,  USA) and p values of < 0.05 were regarded to be 
statistically significant (two-tailed).
Results
Clinical characteristics. The clinical characteris-
tics of the 672 male Chinese subjects (358 prostate can-
cer patients and 314 controls) are shown in Table 1.  The 
mean age at diagnosis of cancer patients and mean age 
at inclusion of control subjects were 70.9 and 70.2 years,  
respectively.  The genotype frequency of RAD17 gene 
polymorphism rs1045051 in the control group main-
tained Hardy-Weinberg equilibrium (p = 0.917).  The 
allele and genotype frequencies of RAD17 gene poly-
morphism rs1045051 among cases and control subjects 
are listed in Table 2.
SNP analysis of RAD17 in prostate cancer. The 
percentage of prostate cancer patients with the RAD17 
gene polymorphism rs1045051 C allele was 37.2%,  vs. 
31.2% for control subjects (Table 2).  The percentages of 
prostate cancer patients and control subjects with the 
RAD17 gene polymorphism rs1045051 AA genotype 
were 39.1% and 46.8%,  while the percentages for the 
CC genotype were 13.4% and 9.2%,  respectively.
Compared with the AA genotype,  the CC genotype 
increased the risk of prostate cancer (OR = 1.738,  
95%CI: 1.038−2.911,  p = 0.036 and AOR = 1.731,  
95%CI: 1.031−2.908,  p = 0.038).  The AC/CC geno-
types were also related to a higher risk of prostate can-
cer (OR = 1.371,  95%CI: 1.008−1.863,  p=0. 044 and 
AOR=1. 374,  95%CI: 1. 010−1. 870,  p = 0.043).  In 
addition,  the C allele had a statistically significant asso-
ciation with the A allele of RAD17 rs1045051 (p= 0.022).
SNP analysis of RAD17 in localized and advanced 
prostate cancer. In stratified analysis,  patients were 
classified into a localized disease group and advanced 
disease group based on the aggressiveness of the pros-
tate cancer (Table 3).  In the localized disease group (the 
subjects were all cancer-free patients or healthy men),  
the CC genotype of RAD17 gene polymorphism 
rs1045051 still increased the prostate cancer risk com-
pared with the AA genotype (AOR = 2.423,  95%CI:  
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1.286−4.566,  p = 0.006).  The C allele was found to con-
fer an increased risk of prostate cancer compared to the 
A allele of RAD17 rs1045051 (AOR = 1.464,  95%CI:  
1.081−1.982,  p = 0.014).  However,  there was no signif-
icant association between RAD17 rs1045051 and the 
prostate cancer risk in the advanced group.
SNP analysis of RAD17 for ages at diagnosis (≤ 70 
or > 70 years). In another stratified analysis,  the 
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Table 1　 Demographic and clinical characteristics of study subjects
Variables Controls Cases Localized PCa Advanced PCa P value＊
No. of subjects 314 358 128 230
Mean age (SD) 70.2 (9.9) 70.9 (9.1) 71.3 (8.9) 70.7 (9.2) 0.358
Mean PSA (SD) 2.8 (1.3) 37.4 (78.8) 24.7 (36.5) 44.5 (93.8) 0.000
Smoking status No. (%) 0.594
　Never 220 (70.1) 244 (68.2) 85 (66.4) 159 (69.1)
　Ever 94 (29.9) 114 (31.8) 43 (33.6) 71 (30.9)
Drinking status No. (%) 0.283
　Never 261 (83.1) 286 (79.9) 104 (81.3) 182 (79.1)
　Ever 53 (16.9) 72 (20.1) 24 (18.7) 48 (20.9)
Gleason score
　No. of subjects (%) 347 120 227
　2-6 80 (23.1) 51 (42.5) 29 (12.8)
　7 118 (34.0) 60 (50.0) 58 (25.5)
　8-10 149 (42.9) 9 (7.5) 140 (61.7)
Tumor stage＃
　No. (%) 344 119 225
　T1 42 (12.2) 30 (25.2) 12 (5.4)
　T2 142 (41.3) 81 (68.1) 61 (27.1)
　T3 117 (34.0) 6 (5.0) 111 (49.3)
　T4 43 (12.5) 2 (1.7) 41 (18.2)
Nodal stage
　No. (%) 317 117 200
　N0 239 (75.4) 114 (97.4) 125 (62.5)
　N1 78 (24.6) 3 (2.6) 75 (37.5)
Metastasis stage
　No. (%) 342 118 224
　M0 238 (69.6) 116 (98.3) 122 (54.5)
　M1 104 (30.4) 2 (1.7) 102 (45.5)
＊Calculated p values based on data from control subjects and all case subjects.
＃Tumor stage according to the UICC TNM classification.
PCa,  prostate cancer; SD,  standard deviation; PSA,  Prostate-specific antigen.








Crude OR (95% CI) P value Adjusted
＊ OR
(95% CI) P value
rs1045051
AA 147 (46.8) 140 (39.1) 1.000 [Ref.] 1.000 [Ref.]
AC 138 (44.0) 170 (47.5) 1.293 (0.937-1.786) 0.118 1.296 (0.936-1.794) 0.118
CC 29 (9.2) 48 (13.4) 1.738 (1.038-2.911) 0.036 1.731 (1.031-2.908) 0.038
AC/CC 167 (53.2) 218 (60.9) 1.371 (1.008-1.863) 0.044 1.374 (1.010-1.870) 0.043
A 432 (68.8) 450 (62.8) 1.000 [Ref.] 1.000 [Ref.]
C 196 (31.2) 266 (37.2) 1.303 (1.038-1.635) 0.022 1.302 (1.037-1.634) 0.023
＊Adjusted for age,  smoking status and drinking status in a logistic regression model.
SNP,  single-nucleotide polymorphisms; OR,  Odds Ratio; 95% CI,  95% confidential interval.
diagnosis age of 70 years was chosen as the dividing line 
to yield similar numbers of older and younger cases 
(Table 4).  The CC genotype in the group over 70 years 
was significantly associated with the risk of prostate 
cancer (AOR = 1.956,  95%CI: 1.018−3.755,  p = 0.044).
SNP analysis of RAD17 for distinct environment 
exposure factors and clinical characteristics.
Subjects with the AA genotype were significantly dis-
tinct from those with the non-AA genotype in terms of 
the PSA level at diagnosis (ng/mL) (p = 0.007).  
However,  in the analysis of the association between 
RAD17 gene polymorphism rs1045051 and clinical 
characteristics,  there were no significant associations 
with aggressiveness of disease,  Gleason scores,  age at 
diagnosis,  smoking status,  or drinking status (Table 5).
Discussion
Cell cycle checkpoints are the biochemical pathways 
that restrain the cell cycle transition and induce cell 
death after stress [20].  Certain enforcements of cell 
cycle checkpoints,  such as the cellular response to DNA 
damage,  are essential for the maintenance of genomic 
integrity and are activated in the early stages of tumori-
genesis [21].
Albujja et al.  reviewed the studies associating SNPs 
with the occurrence and development of prostate can-
cer,  and summarized the potential predictive biomark-
ers [22],  while RAD17 rs1045051 was found to be 
associated with a risk of prostate cancer in this study.  As 
shown in Fig. 1,  when a missense mutation occurs,  the 
original codon (CUC) mutates into a new codon (CGC),  
resulting in a change of the original amino acid (Leu) to 
Arg.  But unlike in DNA point mutation,  SNPs are 
defined as DNA variants detectable in more than 1% of 
the population [23].  Therefore,  the missense mutation 
occurrence of RAD17 rs1045051 may lead to a change 
in protein functions and RAD17 signaling,  and could 
further cause cell cycle dysregulation,  which is fre-
quently observed in tumor development.
RAD17 is a protein product encoded by Schizo-
saccharomyces pombe cell cycle checkpoint genes and is 
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Table 4　 RAD17 gene polymorphism rs1045051 genotype and allele frequencies [n (%)] and adjusted OR stratified by age at diagnosis
Genotype 
or allele












(95% CI) P value
AA 65 (47.1) 60 (37.7) 1.00 (Ref.) 82 (46.6) 80 (40.2) 1.00 (Ref.)
AC 62 (44.9) 85 (53.5) 1.523 (0.936-2.478) 0.090 76 (43.2) 85 (42.7) 1.129 (0.723-1.762) 0.594
CC 11 (8.0) 14 (8.8) 1.323 (0.552-3.170) 0.530 18 (10.2) 34 (17.1) 1.956 (1.018-3.755) 0.044
AC/CC 73 (52.9) 99 (62.3) 1.491 (0.933-2.381) 0.095 94 (53.4) 119 (59.8) 1.293 (0.854-1.960) 0.225
A 192 (69.6) 205 (64.5) 1.00 (Ref.) 240 (68.2) 245 (61.6) 1.00 (Ref.)
C 84 (30.4) 113 (35.5) 1.258 (0.889-1.779) 0.194 112 (31.8) 153 (38.4) 1.338 (0.988-1.811) 0.060
＊Adjusted for age,  smoking and drinking status in a logistic regression model.
OR,  Odds Ratio; 95% CI,  95% confidential interval.
















(95% CI) P value
AA 147 (46.8) 50 (39.1) 147 (46.8) 90 (39.1)
AC 138 (44.0) 54 (42.2) 1.171 (0.745-1.841) 0.494 138 (44.0) 116 (50.5) 1.365 (0.950-1.963) 0.093
CC 29 (9.2) 24 (18.7) 2.423 (1.286-4.566) 0.006 29 (9.2) 24 (10.4) 1.351 (0.738-2.472) 0.329
AC/CC 167 (53.2) 78 (60.9) 1.395 (0.916-2.124) 0.121 167 (53.2) 140 (60.9) 1.363 (0.963-1.927) 0.080
A 432 (68.8) 154 (60.2) 1.00 (Ref.) 432 (68.8) 296 (64.3) 1.00 (Ref.)
C 196 (31.2) 102 (39.8) 1.464 (1.081-1.982) 0.014 196 (31.2) 164 (35.7) 1.219 (0.944-1.573) 0.129
＊Adjusted for age,  smoking and drinking status in a logistic regression model.
OR,  Odds Ratio; 95% CI,  95% confidential interval.
indispensable in checkpoint control pathways to cope 
with DNA damage and replication disruption [10].  
RAD17 is essential for sustained cell growth,  mainte-
nance of chromosomal stability and ATR-dependent 
checkpoint activation upon DNA damage.  RAD17 may 
also serve as a sensor of DNA replication progression 
and may be involved in homologous recombination.  
Meanwhile,  RAD17 shares strong similarity with DNA 
replication factor C (RFC),  and can form a complex 
with RFCs.  RAD17 has a weak ATPase activity required 
for binding to chromatin,  and recruits the RAD1-
RAD9-HUS1 checkpoint protein complex and RHNO1 
onto chromatin after DNA damage.  In response to 
DNA damage,  RAD17 can also be phosphorylated by 
the checkpoint kinase ATR.  The P-loop (also called the 
Walker A motif),  an indispensable region for the 
nucleotide binding of ATPase’s,  and the C terminus 
with two SQ motifs (Ser635 and Ser645),  which are 
effective targets of ATR kinase,  are the two essential 
regions of this protein [18].  The phosphorylation of 
these two SQ sites is required for the 
DNA-damage-induced cell cycle G2 
arrest,  and is thought to be a criti-
cal early event during checkpoint 
signaling in DNA-damaged cells.  
Another recent study reported that 
the interaction between RAD17-
RFC2-5 and 9-1-1 complexes is also 
relevant to the ATR-Chk1 pathway,  
which is an important checkpoint 
pathway of DNA damage.  And 
iVERGE,  a conserved amino acid 
motif,  at the C-terminal tail of 
RAD17 conserved the Y665 and 
S667 residues.  The phosphorylation of the RAD17- 
S667 residue is significant for the interaction of RAD17 
with the 9-1-1 complex,  but the function of Y665 
would depend on the phosphorylation of RAD17-S667,  
which means that iVERGE combines with manifold 
pathways to regulate ATR-Chk1 [24].  The results above 
show that there might be many direct or indirect links 
between RAD17 and DNA damage; our present exper-
iments were designed to explore one of them.
In this case-control study,  we specifically focused on 
RAD17 and the relation of its single nucleotide poly-
morphism,  rs1045051,  to prostate cancer incidence.  
We found that RAD17 rs1045051 was a risk factor for 
prostate cancer in this Chinese population,  and certain 
mutations in RAD17 rs1045051 are possible genetic 
causes of prostate cancer.  To our knowledge,  our study 
is the first to report an association between RAD17 gene 
polymorphism rs1045051 and prostate cancer risk.
RAD17 has previously been reported as a genetic 
risk factor for other cancers.  A link between RAD17 
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Fig. 1　 The schema of RAD17 rs1045051 and missense mutation.
Table 5　 Association of RAD17 gene polymorphism rs1045051 with clinical characteristics
rs1045051 Aggressiveness ofdisease no. (%) Gleason score [n (%)]





Smoking status Drinking status
Localized Advanced 2-6 7 8-10 <4 4-10 >10 Never Ever Never Ever
No. of subjects 128 230 80 118 149 260 182 230 70.6
(n=672)

























































P value 0.990 0.461 0.007 0.243 0.844 0.280
PSA,  prostate-specific antigen.
rs1045051 and the risk of esophageal squamous cell 
carcinoma was reported in a 2016 study of a Japanese 
population,  and a 2017 study found an association 
between the RAD17 codon 546 polymorphism and the 
risk of colorectal cancer among Japanese [18 , 19].  The 
Arg/Arg genotype of RAD17 rs1045051 was associated 
with higher risk of colorectal cancer in males [18].  In 
our study,  the CC genotype conferred a higher risk of 
prostate cancer in men over the age of 70,  and was also 
associated with an increased risk of localized prostate 
cancer.  Based on the above evidence,  we believe that 
RAD17 is inextricably linked to tumorigenesis.
In conclusion,  the CC genotype and C allele in 
RAD17 gene polymorphism rs1045051 may have a sub-
stantial influence on prostate cancer risk.  Our study 
suggests that RAD17 rs1045051 may be used as a new 
indicator for the diagnosis of prostate cancer or the pre-
diction of treatment efficacy.
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